Key facts
- Notable investors include Dalton Venture, Chuangyuan High-tech Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Xizi Shenghe
- ·The full record, as it builds
Funding rounds
No funding rounds for Xizi Shenghe are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xizi Shenghe
Developer of a biotechnology research enterprise designed to advance biomedical innovation. The company offers antibody discovery, mRNA preparation, nucleic acid synthesis, and enzyme evolution technologies, enabling biotechnology companies and research institutions to accelerate drug development and enhance research efficiency.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Xizi Shenghe doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xizi Shenghe shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xizi Shenghe in its N-PORT filings yet. We sweep new filings monthly.